By the end of September 2015, NPO Petrovax Pharm will supply over 3m Grippol® Plus flu vaccine doses to Belarus. Under the government contract signed in July with Belpharmatsiya, the Belarusian public pharmacy chain, Petrovax Pharm will be the sole supplier of anti-flu vaccines to Belarus over the 2015–2016 epidemic season as part of the National Immunisation Schedule. To date, the country has already received 25% of the total vaccine doses.
The supply of Grippol® Plus flu vaccines under the government contract is an early stage of a long-term partnership programme, with joint strategic development plans involving localising production at Belmedpreparaty, the largest pharmaceutical producer locally.
Petrovax Pharm has been enjoying success in the Belarusian pharmaceutical market for over 9 years now, and the Company's major products, Polyoxidonium® and Grippol® Plus, are widely used in medical practice throughout the country.
President of NPO Petrovax Pharm Elena Arkhangelskaya said: “This year, it is the first time we supply anti-flu vaccines to Belarus under the government contract, which is an important step for Petrovax to boost international cooperation and export potential. We would like to thank the Belarusian Ministry of Health for placing their trust in the Company and we hope our win-win relationship will see further development. Through our well-coordinated joint efforts, by the start of the new influenza season people across Belarus will be provided free of charge with our modern high-quality Grippol® Plus vaccine, which is produced in compliance with international GMP standards.”
Petrovax Pharm is Russia's largest producer and supplier of anti-flu vaccines. Since 2009, Grippol® Plus is purchased as part of the National Immunisation Schedule. Over 7 years of its use, a total of more than 100 million people have been vaccinated.
Due to its strong efficacy, high quality and safety profile, Grippol® Plus vaccine is exported to a number of CIS countries. Apart from Belarus, Grippol® Plus is registered for use in Georgia, Kazakhstan, Kyrgyzstan, Moldova, and Ukraine. In the short-term, the Company plans to start supplying the vaccine to Uzbekistan, with the next step being a foray into EU, Middle East, and Latin America markets.
About the vaccine
Grippol® Plus is a Russian latest-generation adjuvanted subunit preservative-free inactivated influenza vaccine of proven high performance and excellent acceptability. This predetermines its extensive use by adults and children, including infants of 6 months and older, pregnant women, people with chronic somatic diseases, including cardiovascular pathology, allergic disorders and immunodeficiency of various origins. The composition of the vaccine for use in the upcoming influenza season is changed annually as per WHO recommendations. It is made at a modern production facility in compliance with international GMP standards.